Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 262 articles:
HTML format
Text format



Single Articles


    December 2017
  1. ZOULIM F
    Inhibition of hepatitis B virus gene expression: a step towards functional cure.
    J Hepatol. 2017 Dec 4. pii: S0168-8278(17)32480.
    PubMed     Text format    


    November 2017
  2. HARTL J, Ehlken H, Sebode M, Peiseler M, et al
    Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.
    J Hepatol. 2017 Nov 24. pii: S0168-8278(17)32445.
    PubMed     Text format     Abstract available


  3. KUBILIUN M, Patel SJ, Hur C, Dienstag JL, et al
    Early liver transplantation for alcoholic hepatitis: Ready for primetime?
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32452.
    PubMed     Text format    


  4. HUPA KL, Deterding K, Port K, Kimmann M, et al
    In Reply to: EASL RECOMMENDATIONS ON TREATMENT OF HEPATITIS C 2016 "Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?"
    J Hepatol. 2017 Nov 21. pii: S0168-8278(17)32443.
    PubMed     Text format    


  5. FORREST EH, Atkinson SR, Richardson P, Masson S, et al
    Application of Prognostic Scores in The Stopah Trial: Discriminant Function is no Longer the Optimal Scoring System in Alcoholic Hepatitis.
    J Hepatol. 2017 Nov 21. pii: S0168-8278(17)32440.
    PubMed     Text format     Abstract available


  6. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    PubMed     Text format     Abstract available


  7. TANG Y, Li H, Li J, Liu Y, et al
    Macrophage scavenger receptor 1 contributes to pathogenesis of fulminant hepatitis via neutrophil mediated complement activation.
    J Hepatol. 2017 Nov 14. pii: S0168-8278(17)32433.
    PubMed     Text format     Abstract available


  8. BUGGISCH P, Vermehren J, Mauss S, Gunther R, et al
    Real-world effectiveness of 8 weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32431.
    PubMed     Text format     Abstract available


  9. OSSEMAN Q, Gallucci L, Au S, Cazenave C, et al
    The chaperone dynein LL1 mediates cytoplasmic transport of empty and mature hepatitis B virus capsids.
    J Hepatol. 2017 Nov 4. pii: S0168-8278(17)32424.
    PubMed     Text format     Abstract available


  10. CARRIERI MP, Protopopescu C, Marcellin F, Wittkop L, et al
    The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients.
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32406.
    PubMed     Text format    


  11. JANSSEN HLA, Brunetto MR, Kim YJ, Ferrari C, et al
    Safety, Efficacy and Pharmacodynamics of Vesatolimod (GS-9620) in Virally-Suppressed Patients with Chronic Hepatitis B.
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32408.
    PubMed     Text format     Abstract available


    October 2017
  12. MURCIA O, Carnicer F, Gomez-Escolar L, Miralles C, et al
    Direct antiviral agents against Hepatitis C virus: beneficial or harmful?
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32407.
    PubMed     Text format    


  13. POLLMANN J, Gotz JJ, Rupp D, Strauss O, et al
    Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32400.
    PubMed     Text format     Abstract available


  14. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    PubMed     Text format     Abstract available


  15. LONDONO MC, Forns X, Pascasio JM
    Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32385.
    PubMed     Text format    


  16. FRASER H, Martin NK, Brummer-Korvenkontio H, Carrieri P, et al
    Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32387.
    PubMed     Text format     Abstract available


  17. AZAB M, Shah S, Liu X, Ukken J, et al
    Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32390.
    PubMed     Text format    


  18. MUELLER H, Wildum S, Luangsay S, Walther J, et al
    A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393.
    PubMed     Text format     Abstract available


  19. BERG T, Petersen J
    Predicting long-term response after stopping nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B.
    J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32345.
    PubMed     Text format    


  20. YIP TC, Wong GL, Wong VW, Tse YK, et al
    Durability of Hepatitis B Surface Antigen Seroclearance in Untreated and Nucleos(t)ide Analogue-Treated Patients.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32332.
    PubMed     Text format     Abstract available


  21. HALFON P, Scholtes C, Izopet J, Larrat S, et al
    Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.
    J Hepatol. 2017 Oct 4. pii: S0168-8278(17)32333.
    PubMed     Text format     Abstract available


    September 2017
  22. LIEBER SR, Rice JP, Lucey MR, Bataller R, et al
    Controversies in Clinical Trials for Alcoholic Hepatitis.
    J Hepatol. 2017 Sep 28. pii: S0168-8278(17)32325.
    PubMed     Text format     Abstract available


  23. DI MAIO VC, Cento V, Aragri M, Paolucci S, et al
    Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: what are the chances for second-line regimens?
    J Hepatol. 2017 Sep 20. pii: S0168-8278(17)32288.
    PubMed     Text format    


  24. LIU X, Shen JJ, Jung Kim S, Lee YJ, et al
    Necessity of time series analysis and effects of direct-acting antivirals on HCV patients awaiting liver transplantation.
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32290.
    PubMed     Text format    


  25. ESMAT G, Elbaz T, El Raziky M, Gomaa A, et al
    Effectiveness of ravidasvir plus sofosbuvir in interferon-naive and treated patients with chronic hepatitis c genotype-4.
    J Hepatol. 2017 Sep 18. pii: S0168-8278(17)32286.
    PubMed     Text format     Abstract available


  26. PRENNER S, Kulik L
    Reply to "Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma".
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32283.
    PubMed     Text format    


  27. CARRIERI MP, Protopopescu C, Marcellin F, Rosellini S, et al
    Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.
    J Hepatol. 2017 Sep 12. pii: S0168-8278(17)32211.
    PubMed     Text format     Abstract available


  28. FANGAZIO S, Camatta D, Minh MT, Ceriani E, et al
    Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma.
    J Hepatol. 2017 Sep 7. pii: S0168-8278(17)32280.
    PubMed     Text format    


  29. IOANNOU GN, Green PK, Berry K
    HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32273.
    PubMed     Text format     Abstract available


  30. KO HL, Lam TH, Ng H, Toh J, et al
    Identification of Slug and Sox7 as transcriptional repressors binding to the Hepatitis B Virus Core Promoter.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32276.
    PubMed     Text format     Abstract available


  31. QI X, Liu F, Li Z, Chen S, et al
    Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32277.
    PubMed     Text format    


  32. LEMON SM, Ott JJ, Van Damme P, Shouval D, et al
    Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32278.
    PubMed     Text format     Abstract available


  33. IRANMANESH P, Toso C
    Reply to the Letter to the Editor by Qi et al. entitled "Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis".
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32274.
    PubMed     Text format    


  34. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Premature ovarian senescence and high miscarriage rate impair fertility in women with hepatitis C virus infection.
    J Hepatol. 2017 Sep 4. pii: S0168-8278(17)32259.
    PubMed     Text format     Abstract available


  35. HUANG R, Liu Y, Wang J, Xia J, et al
    Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32270.
    PubMed     Text format    


  36. YIP TC, Chan HL, Wong VW, Wong GL, et al
    Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance".
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32266.
    PubMed     Text format    


    August 2017
  37. CALVARUSO V, Craxi A
    HBV recurrence after HCV clearance on DAAs: Sometimes They Come Back.
    J Hepatol. 2017 Aug 29. pii: S0168-8278(17)32256.
    PubMed     Text format    


  38. MALLET V, Bruneau J, Zuber J, Alanio C, et al
    Hepatitis E Virus-Induced Primary Cutaneous CD30(+) T cell Lymphoproliferative Disorder.
    J Hepatol. 2017 Aug 28. pii: S0168-8278(17)32250.
    PubMed     Text format     Abstract available


  39. KRAMER L, Laurain A, Sultanik P, Tremeaux P, et al
    "Empirical" retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32251.
    PubMed     Text format    


  40. GARVEY P, Murphy N, Flanagan P, Brennan A, et al
    Disease Outcomes in a Cohort of Women Infected by Hepatitis C-Contaminated anti-D Immunoglobulin During 1970s.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32249.
    PubMed     Text format     Abstract available


  41. MELE D, Mantovani S, Oliviero B, Grossi G, et al
    Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56bright NK cells.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32203.
    PubMed     Text format     Abstract available


  42. DONATO MF, Invernizzi F, Rossi G, Iavarone M, et al
    Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32200.
    PubMed     Text format    


  43. WAZIRY R, Hajarizadeh B, Grebely J, Amin J, et al
    Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32199.
    PubMed     Text format     Abstract available


  44. DONG YANG J, Leise MD
    Reply to " Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".
    J Hepatol. 2017 Aug 8. pii: S0168-8278(17)32201.
    PubMed     Text format    


  45. ZEUZEM S, Dvory-Sobol H, Brainard DM
    No Effect Of Resistance-Associated Substitutions In Patients With Rare HCV Subtypes Following Treatment With Sofosbuvir-Containing Regimens.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32191.
    PubMed     Text format    


  46. DA SILVA FILIPE A, Sreenu V, Hughes J, Aranday-Cortes E, et al
    Response to DAA Therapy in the NHS England Early Access Programme for Rare HCV Subtypes from Low and Middle Income Countries.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32195.
    PubMed     Text format    


    July 2017
  47. LAZARUS JV, Wiktor S, Colombo M, Thursz M, et al
    Micro-elimination - A path to global elimination of hepatitis C.
    J Hepatol. 2017 Jul 28. pii: S0168-8278(17)32141.
    PubMed     Text format    


  48. SUDA T, Shimakami T, Shirasaki T, Yamashita T, et al
    Reactivation of Hepatitis B Virus from an isolated Anti-HBc positive patient after eradication of Hepatitis C Virus with Direct-acting Antiviral Agents.
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32158.
    PubMed     Text format    


  49. LOK AS, Zoulim F, Dusheiko G, Ghany MG, et al
    Hepatitis B cure: From discovery to regulatory approval.
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32017.
    PubMed     Text format     Abstract available


  50. RAJORIYA N, Combet C, Zoulim F, Janssen HLA, et al
    How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualized approach?
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32154.
    PubMed     Text format     Abstract available


  51. DALTON HR, van Eijk JJJ, Cintas P, Madden RG, et al
    Hepatitis E Virus Infection and Acute Non-Traumatic Neurological Injury: A Prospective Multicentre Study.
    J Hepatol. 2017 Jul 19. pii: S0168-8278(17)32153.
    PubMed     Text format     Abstract available


  52. SAMJI H, Yu A, Kuo M, Alavi M, et al
    Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.
    J Hepatol. 2017 Jul 3. pii: S0168-8278(17)32133.
    PubMed     Text format     Abstract available


    June 2017

  53. Response to the Cochrane Systematic Review on DAA-Based Treatment of Chronic Hepatitis C.
    J Hepatol. 2017 Jun 29. pii: S0168-8278(17)32129.
    PubMed     Text format    


  54. YIP TC, Chan HL, Wong VW, Tse YK, et al
    Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Jun 23. pii: S0168-8278(17)32092.
    PubMed     Text format     Abstract available


  55. XIANG X, You XM, Zhong JH, Li LQ, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32081.
    PubMed     Text format    


  56. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    PubMed     Text format     Abstract available


  57. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32075.
    PubMed     Text format    


  58. NAGATA H, Nakagawa M, Asahina Y, Sato A, et al
    Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    J Hepatol. 2017 Jun 13. pii: S0168-8278(17)32070.
    PubMed     Text format     Abstract available


  59. SUSSER S, Dietz J, Schlevogt B, Zuckerman E, et al
    Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.
    J Hepatol. 2017 Jun 12. pii: S0168-8278(17)32069.
    PubMed     Text format     Abstract available


  60. DURIEZ M, Mandouri Y, Lekbaby B, Wang H, et al
    Alternative splicing of Hepatitis B virus: a novel virus/host interaction altering liver immunity.
    J Hepatol. 2017 Jun 6. pii: S0168-8278(17)32065.
    PubMed     Text format     Abstract available


    May 2017
  61. PEMBROKE T, Deschenes M, Lebouche B, Benmassaoud A, et al
    Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32047.
    PubMed     Text format     Abstract available


  62. ANDREASSON K, Waldenstrom J, Westin J, Norrgren H, et al
    JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32044.
    PubMed     Text format    


  63. COLPITTS CC, Baumert TF
    SCARB1 variants and HCV infection: Host susceptibility is lost in translation.
    J Hepatol. 2017 May 3. pii: S0168-8278(17)30255.
    PubMed     Text format    


  64. WENDON, J, Cordoba J, Dhawan A, Larsen FS, et al
    EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure.
    J Hepatol. 2017;66:1047-1081.
    PubMed     Text format     Abstract available


  65. MRIDHA AR, Wree A, Robertson AAB, Yeh MM, et al
    NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    J Hepatol. 2017;66:1037-1046.
    PubMed     Text format     Abstract available


    April 2017
  66. BANKWITZ D, Doepke M, Hueging K, Weller R, et al
    Maturation of secreted HCV particles by incorporation of secreted apoE protects from antibodies by enhancing infectivity.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30251.
    PubMed     Text format     Abstract available


  67. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30249.
    PubMed     Text format     Abstract available


  68. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    PubMed     Text format    


  69. HALLAGER S, Ladelund S, Weis N
    Methodological considerations when calculating person time at risk for patients with chronic hepatitis C undergoing antiviral treatment.
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30218.
    PubMed     Text format    


  70. LOUVET A, Peck-Radosavljevic M
    Evidence for a role of genetics in alcoholic hepatitis: data from the STOPAH randomized controlled trial.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30210.
    PubMed     Text format    


  71. LENGGENHAGER D, Gouttenoire J, Malehmir M, Bawohl M, et al
    Visualization of hepatitis E virus RNA and proteins in the human liver.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30212.
    PubMed     Text format     Abstract available


  72. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Text format     Abstract available


  73. THONS C, Senff T, Hydes TJ, Manser AR, et al
    HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30213.
    PubMed     Text format     Abstract available


  74. VAN SANTEN DK, Van Der Helm JJ, Del Amo J, Meyer L, et al
    Lack of decline in Hepatitis C Virus incidence among HIV-positive men who have sex with men during 1990-2014.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30209.
    PubMed     Text format     Abstract available


  75. ZIMMERMANN R, Kollan C, Ingiliz P, Mauss S, et al
    Reply to "Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030".
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30204.
    PubMed     Text format    


  76. DORE GJ, Grebely J
    Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30206.
    PubMed     Text format    


  77. TUMINO N, Casetti R, Fabbri G, Cimini E, et al
    In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30207.
    PubMed     Text format    


  78. HASSON H, Merli M, Messina E, Bhoori S, et al
    Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30203.
    PubMed     Text format     Abstract available


  79. LANGHANS B
    Reply to "In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals".
    J Hepatol. 2017 Apr 9. pii: S0168-8278(17)30205.
    PubMed     Text format    


  80. SCHWARZINGER M, Baillot S, Yazdanpanah PY, Rehm PJ, et al
    Contribution of Alcohol Use Disorders on the Burden of Chronic Hepatitis C in France, 2008-2013: A Nationwide Retrospective Cohort Study.
    J Hepatol. 2017 Apr 7. pii: S0168-8278(17)30202.
    PubMed     Text format     Abstract available


  81. SHIRVANI-DASTGERDI E, Winer BY, Celia-Terrassa A, Kang Y, et al
    Selection of the highly replicative and partially multidrug resistant rtS78T polymerase mutation in two patients with chronic hepatitis B virus infection during tenofovir-entecavir combination therapy.
    J Hepatol. 2017 Apr 6. pii: S0168-8278(17)30198.
    PubMed     Text format     Abstract available


    March 2017
  82. WESTHAUS S, Deest M, Nguyen AT, Stanke F, et al
    Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load.
    J Hepatol. 2017 Mar 28. pii: S0168-8278(17)30184.
    PubMed     Text format     Abstract available



  83. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
    J Hepatol. 2017 Mar 27. pii: S0168-8278(17)30185.
    PubMed     Text format     Abstract available


  84. WELZEL T, Bhardwaj N, Hedskog C, Chodavarapu K, et al
    Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses.
    J Hepatol. 2017 Mar 23. pii: S0168-8278(17)30148.
    PubMed     Text format     Abstract available


  85. MARTIN NK, Vickerman P, Hickman M
    How to eliminate HCV infection by antiviral treatment.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30142.
    PubMed     Text format    


  86. BRUNETTO M, Cornberg M, Chan HL
    How Good Is Hepatitis B Surface Antigen Kinetics Informing Strategy to Stop Antiviral Therapy?
    J Hepatol. 2017 Mar 15. pii: S0168-8278(17)30136.
    PubMed     Text format    


  87. MALLET V, Hamed K, Schwarzinger M
    Erratum to "Prognosis of patients with chronic hepatitis B in France (2008-2013): A nationwide, observational and hospital-based study".
    J Hepatol. 2017 Mar 8. pii: S0168-8278(17)30112.
    PubMed     Text format    


  88. BESTE LA, Green PK, Berry K, Kogut MJ, et al
    Effectiveness of hepatitis c antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30126.
    PubMed     Text format     Abstract available


    February 2017
  89. PIROTH L, Wittkop L, Lacombe K, Rosenthal E, et al
    Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-coinfected patients - French ANRS CO13 HEPAVIH cohort.
    J Hepatol. 2017 Feb 21. pii: S0168-8278(17)30107.
    PubMed     Text format     Abstract available


  90. RAMOS-CASALS M, Zignego AL, Ferri C, Brito-Zeron P, et al
    Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.
    J Hepatol. 2017 Feb 17. pii: S0168-8278(17)30105.
    PubMed     Text format     Abstract available


  91. YAN Z, Zeng J, Yu Y, Xiang K, et al
    HBVcircle: a Novel Tool to Investigate Hepatitis B Virus Covalently Closed Circular DNA.
    J Hepatol. 2017 Feb 14. pii: S0168-8278(17)30072.
    PubMed     Text format     Abstract available


  92. OLIVIERO B, Mantovani S, Varchetta S, Mele D, et al
    Hepatitis C virus-Induced NK Cell Activation Causes Metzincin-Mediated CD16 Cleavage and Impaired Antibody-Dependent Cytotoxicity.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30069.
    PubMed     Text format     Abstract available


  93. CABIBBO G, Petta S, Barbara M, Attardo S, et al
    Hepatic Decompensation is the Major Driver of Death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30070.
    PubMed     Text format     Abstract available


  94. ZENG QL, Xu GH, Zhang JY, Li W, et al
    Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30060.
    PubMed     Text format     Abstract available


  95. ZIMMERMANN R, Kollan C, Ingiliz P, Mauss S, et al
    Real-world treatment for chronic hepatitis C infection in Germany. Analyses from drug prescription data, 2010 - 2015.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30059.
    PubMed     Text format     Abstract available


  96. CALLEJA JL, Crespo J, Rincon D, Ruiz-Antoran B, et al
    Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real world cohort.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30063.
    PubMed     Text format     Abstract available


  97. GREBELY J, Swan T, Hickman M, Bruneau J, et al
    Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30054.
    PubMed     Text format    


  98. PAWLOTSKY JM
    Consistent advice for people who inject drugs in the 2016 EASL Recommendations on treatment of hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30055.
    PubMed     Text format    


  99. ATKINSON SR, Way MJ, McQuillin A, Morgan MY, et al
    Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30051.
    PubMed     Text format     Abstract available


  100. PRENNER S, VanWagner LB, Flamm SL, Salem R, et al
    Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Virus Therapy with Direct-Acting Antivirals.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30053.
    PubMed     Text format     Abstract available


    January 2017
  101. FARQUHAR MJ, Humphreys IS, Rudge SA, Wilson GK, et al
    Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
    J Hepatol. 2017 Jan 23. pii: S0168-8278(17)30013.
    PubMed     Text format     Abstract available


  102. ZEUZEM S, Mizokami M, Pianko S, Mangia A, et al
    NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus: Prevalence and Effect on Treatment Outcome.
    J Hepatol. 2017 Jan 17. pii: S0168-8278(17)30011.
    PubMed     Text format     Abstract available


  103. FILLIOL A, Piquet-Pellorce C, Raguenes-Nicol C, Dion S, et al
    RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis.
    J Hepatol. 2017 Jan 11. pii: S0168-8278(17)30009.
    PubMed     Text format     Abstract available


  104. KLAG T, Dietz J, Werner CR, Schwarz JM, et al
    Hepatitis C "true" late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30006.
    PubMed     Text format    


    December 2016
  105. LEBOSSE F, Testoni B, Fresquet J, Facchetti F, et al
    Intrahepatic innate immune response pathways are down-regulated in untreated chronic hepatitis B.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30757.
    PubMed     Text format     Abstract available


  106. LANGHANS B, Dieter Nischalke H, Kramer B, Hausen A, et al
    Increased peripheral cd4+ regulatory t cells persist after successful direct-acting antiviral treatment of chronic hepatitis C.
    J Hepatol. 2016 Dec 28. pii: S0168-8278(16)30752.
    PubMed     Text format     Abstract available


  107. FERNANDEZ I, Munoz-Gomez R, Pascasio JM, Baliellas C, et al
    Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis c.
    J Hepatol. 2016 Dec 27. pii: S0168-8278(16)30753.
    PubMed     Text format     Abstract available


  108. VUKOTIC R, Conti F, Andreone P
    Hepatitis C virus eradication in elderly: The challenge worth a long-life elixir?
    J Hepatol. 2016 Dec 21. pii: S0168-8278(16)30745.
    PubMed     Text format    


  109. VERRIER ER, Schuster C, Baumert TF
    Advancing hepatitis B virus entry inhibitors.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30706.
    PubMed     Text format    


  110. MANGIA A, Susser S, Piazzolla V, Agostinacchio E, et al
    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30707.
    PubMed     Text format     Abstract available


  111. NI Y, Urban S
    Stem cell-derived hepatocytes: a promising novel tool to study Hepatitis B Virus infection.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30704.
    PubMed     Text format    


  112. WYLES D, Dvory-Sobol H, Svarovskaia Doehle ES, Martin R, et al
    Post-Treatment Resistance Analysis of Hepatitis C Virus from Phase 2 and 3 Clinical Trials of Ledipasvir/ Sofosbuvir.
    J Hepatol. 2016 Dec 3. pii: S0168-8278(16)30699.
    PubMed     Text format     Abstract available


    November 2016
  113. PISCHKE S, Hartl J, Pas SD, Lohse AW, et al
    Hepatitis E virus infection beyond the liver?
    J Hepatol. 2016 Nov 29. pii: S0168-8278(16)30692.
    PubMed     Text format     Abstract available


  114. ZIEMER M, Koukoulioti E, Beyer S, Simon JC, et al
    Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids.
    J Hepatol. 2016 Nov 28. pii: S0168-8278(16)30691.
    PubMed     Text format    


  115. NOTARPAOLO A, Layese R, Magistri P, Gambato M, et al
    Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    J Hepatol. 2016 Nov 26. pii: S0168-8278(16)30688.
    PubMed     Text format     Abstract available


  116. TOYODA H, Kumada T, Tada T, Shimada N, et al
    Efficacy and Tolerability of an IFN-free Regimen with DCV/ASV for Elderly Patients Infected with HCV Genotype 1B.
    J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30686.
    PubMed     Text format     Abstract available


  117. SHIMURA S, Watashi K, Fukano K, Peel M, et al
    Cyclosporin derivatives inhibit hepatitis B virus entry without interfering the NTCP transporter.
    J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30683.
    PubMed     Text format     Abstract available


  118. HELLARD M, Pedrana A, Scott N
    Targeted direct-acting antiviral treatment for chronic hepatitis C: a financial reality or an obstacle to elimination?
    J Hepatol. 2016 Nov 21. pii: S0168-8278(16)30680.
    PubMed     Text format    


  119. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    PubMed     Text format    


  120. MALLET V, Hamed K, Schwarzinger M
    Prognosis of Patients with Chronic Hepatitis B in France (2008-2013): A Nationwide, Observational and Hospital-based Study.
    J Hepatol. 2016 Nov 5. pii: S0168-8278(16)30642.
    PubMed     Text format     Abstract available


  121. WANG J, Du M, Huang H, Chen R, et al
    Consistent loss of serum HBV RNA might predict the "para-functional cure" of chronic hepatitis B.
    J Hepatol. 2016 Nov 5. pii: S0168-8278(16)30645.
    PubMed     Text format    


  122. JANJUA NZ, Chong M, Kuo M, Woods R, et al
    Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    J Hepatol. 2016 Nov 3. pii: S0168-8278(16)30637.
    PubMed     Text format     Abstract available


  123. FALADE-NWULIA O, Sulkowski M
    The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection.
    J Hepatol. 2016 Nov 2. pii: S0168-8278(16)30636.
    PubMed     Text format    


    October 2016
  124. VAN DER MEER AJ, Feld JJ, Hofer H, Almasio PL, et al
    Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    J Hepatol. 2016 Oct 22. pii: S0168-8278(16)30582.
    PubMed     Text format     Abstract available


  125. LEMOINE M, Thursz MR
    Field battle against hepatitis B infection and HCC in Africa.
    J Hepatol. 2016 Oct 19. pii: S0168-8278(16)30578.
    PubMed     Text format     Abstract available


  126. BEGUELIN C, Moradpour D, Sahli R, Suter-Riniker F, et al
    Hepatitis delta-associated mortality in HIV/HBV-coinfected patients.
    J Hepatol. 2016 Oct 13. pii: S0168-8278(16)30569.
    PubMed     Text format     Abstract available


  127. XIA Y, Carpentier A, Cheng X, Block PD, et al
    Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions.
    J Hepatol. 2016 Oct 13. pii: S0168-8278(16)30572.
    PubMed     Text format     Abstract available


  128. DEUFFIC-BURBAN S, Boursier J, Leroy V, Yazdanpanah Y, et al
    Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?
    J Hepatol. 2016 Oct 12. pii: S0168-8278(16)30568.
    PubMed     Text format     Abstract available


  129. ROSS DB, Belperio PS, Chartier M, Backus LI, et al
    Hepatitis C Testing in U.S. Veterans Born 1945-1965: An Update.
    J Hepatol. 2016 Oct 5. pii: S0168-8278(16)30557.
    PubMed     Text format    


  130. JUSTICE AC, Esserman D, Sarkar S, Levin FL, et al
    Reply to: "Disparities in Hepatitis C Testing in U.S. Veterans Born 1945-1965".
    J Hepatol. 2016 Oct 4. pii: S0168-8278(16)30558.
    PubMed     Text format    


  131. VAN DER MEER AJ, Berenguer M
    Reversion of disease manifestations after HCV eradication.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  132. CACOUB P, Desbois AC, Isnard-Bagnis C, Rocatello D, et al
    Hepatitis C virus infection and chronic kidney disease: Time for reappraisal.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  133. MAASOUMY B, Vermehren J
    Diagnostics in hepatitis C: The end of response-guided therapy?
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  134. EASTERBROOK PJ
    Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  135. MIDGARD H, Weir A, Palmateer N, Lo Re V 3rd, et al
    HCV epidemiology in high-risk groups and the risk of reinfection.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  136. HEIM MH, Bochud PY, George J
    Host - hepatitis C viral interactions: The role of genetics.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  137. BUKH J
    The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  138. MORADPOUR D, Grakoui A, Manns MP
    Future landscape of hepatitis C research - Basic, translational and clinical perspectives.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  139. YOUNOSSI ZM, Birerdinc A, Henry L
    Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  140. FORNS X, Berg T
    Hepatitis C virus - A teacher of clinical research, cell biology and immunology.
    J Hepatol. 2016;65.
    PubMed     Text format    


  141. VAN DER VALK M, Zaaijer HL, Kater AP, Schinkel J, et al
    Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection.
    J Hepatol. 2016 Oct 1. pii: S0168-8278(16)30541.
    PubMed     Text format    


    September 2016
  142. CHAYANUPATKUL M, Omino R, Mittal S, Kramer JR, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2016 Sep 28. pii: S0168-8278(16)30540.
    PubMed     Text format     Abstract available


  143. INGILIZ P, Martin TC, Rodger A, Stellbrink HJ, et al
    HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.
    J Hepatol. 2016 Sep 17. pii: S0168-8278(16)30505.
    PubMed     Text format     Abstract available


  144. XIANG KH, Michailidis E, Ding H, Peng YQ, et al
    Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA.
    J Hepatol. 2016 Sep 17. pii: S0168-8278(16)30506.
    PubMed     Text format     Abstract available


  145. LAI CL, Wong D, Ip P, Kopaniszen M, et al
    Reduction of Covalently Closed Circular DNA with Long-term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B.
    J Hepatol. 2016 Sep 14. pii: S0168-8278(16)30487.
    PubMed     Text format     Abstract available



  146. EASL Recommendations on Treatment of Hepatitis C 2016.
    J Hepatol. 2016 Sep 12. pii: S0168-8278(16)30489.
    PubMed     Text format    


  147. POL S, Bourliere M, Lucier S, Hezode C, et al
    Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    J Hepatol. 2016 Sep 10. pii: S0168-8278(16)30486.
    PubMed     Text format     Abstract available


  148. WANG H, Tai AW
    Continuous de novo generation of spatially segregated hepatitis C virus replication organelles revealed by pulse-chase imaging.
    J Hepatol. 2016 Sep 3. pii: S0168-8278(16)30483.
    PubMed     Text format     Abstract available


  149. RIZZETTO M, Niro GA
    Myrcludex B, a novel therapy for chronic hepatitis D?
    J Hepatol. 2016;65:465-6.
    PubMed     Text format    


    August 2016
  150. ZAVAGLIA C, Okolicsanji S, Cesarini L, Mazzarelli C, et al
    Is the risk of neoplastic recurrence increased after prescribing Direct Acting Antivirals for HCV patients whose HCC was previously cured?
    J Hepatol. 2016 Aug 31. pii: S0168-8278(16)30481.
    PubMed     Text format    


  151. CORNBERG M, Wong VW, Locarnini S, Brunetto M, et al
    The role of quantitative hepatitis b surface antigen revisited.
    J Hepatol. 2016 Aug 26. pii: S0168-8278(16)30441.
    PubMed     Text format     Abstract available


  152. WAZIRY R, Grebely J, Amin J, Alavi M, et al
    Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).
    J Hepatol. 2016 Aug 25. pii: S0168-8278(16)30442.
    PubMed     Text format     Abstract available


  153. FUNG S, Kwan P, Fabri M, Horban A, et al
    Tenofovir disoproxil fumarate (TDF) versus TDF/emtricitabine (FTC) in lamivudine-resistant hepatitis B: a 5-year randomized study.
    J Hepatol. 2016 Aug 18. pii: S0168-8278(16)30440.
    PubMed     Text format     Abstract available


  154. INNES H, McDonald S, Hayes P, Dillon JF, et al
    Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population.
    J Hepatol. 2016 Aug 18. pii: S0168-8278(16)30428.
    PubMed     Text format     Abstract available


  155. HEDEGAARD DL, Tully DC, Rowe IA, Reynolds GM, et al
    High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end stage liver disease.
    J Hepatol. 2016 Aug 13. pii: S0168-8278(16)30424.
    PubMed     Text format     Abstract available


  156. MINAMI T, Tateishi R, Nakagomi R, Fujiwara N, et al
    The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma.
    J Hepatol. 2016 Aug 11. pii: S0168-8278(16)30419.
    PubMed     Text format    


  157. ROBAEYS G, Rob B, Azar DG, Razavi H, et al
    Global genotype distribution of hepatitis C viral infection among people who inject drugs.
    J Hepatol. 2016 Aug 9. pii: S0168-8278(16)30418.
    PubMed     Text format     Abstract available


  158. EBERHARD JM, Kummer S, Hartjen P, Hufner A, et al
    Reduced CD161+MAIT cell frequencies in HCV and HIV/HCV co-infection. Is the liver the heart of the matter?
    J Hepatol. 2016 Aug 1. pii: S0168-8278(16)30401.
    PubMed     Text format     Abstract available


    July 2016
  159. CARDOSO H, Vale AM, Rodrigues S, Goncalves R, et al
    High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis.
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30397.
    PubMed     Text format    


  160. ZENG QL, Li ZQ, Liang HX, Xu GH, et al
    Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30399.
    PubMed     Text format    


  161. VIONNET J, Saouli AC, Pascual M, Stucker F, et al
    Therapeutic Drug Monitoring for Sofosbuvir and Daclatasvir in Transplant Recipients with Chronic Hepatitis C and Advanced Renal Disease.
    J Hepatol. 2016 Jul 25. pii: S0168-8278(16)30347.
    PubMed     Text format    


  162. DEGASPERI E, De Nicola S, Rumi M, D'Ambrosio R, et al
    HCV-RNA Kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.
    J Hepatol. 2016 Jul 23. pii: S0168-8278(16)30344.
    PubMed     Text format    


  163. DESNOYER A, Le MP, Yazdanpanah Y, Peytavin G, et al
    Reply to: "Therapeutic Drug Monitoring for Sofosbuvir and Daclatasvir in Transplant Recipients with Chronic Hepatitis C and Advanced Renal Disease".
    J Hepatol. 2016 Jul 23. pii: S0168-8278(16)30345.
    PubMed     Text format    


  164. MAASOUMY B, Vermehren J, Wedemeyer H, Sarrazin C, et al
    Clinical value of on-treatment HCV-RNA levels during treatment with sofosbuvir and ribavirin in genotype 3 patients.
    J Hepatol. 2016 Jul 23. pii: S0168-8278(16)30343.
    PubMed     Text format    


  165. YAMASHITA T, Nault JC
    Stemness of liver cancer: from hepatitis B virus to Wnt activation.
    J Hepatol. 2016 Jul 19. pii: S0168-8278(16)30338.
    PubMed     Text format    


  166. LI TC, Zhou X, Yoshizaki S, Ami Y, et al
    Production of Infectious Dromedary Camel Hepatitis E Virus by a Reverse Genetic System: Potential for Zoonotic Infection.
    J Hepatol. 2016 Jul 19. pii: S0168-8278(16)30337.
    PubMed     Text format     Abstract available



  167. Joint society statement for the elimination of viral hepatitis.
    J Hepatol. 2016 Jul 15. pii: S0168-8278(16)30339.
    PubMed     Text format    


  168. ALAVI M, Law MG, Grebely J, Amin J, et al
    Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study, 1995-2012.
    J Hepatol. 2016 Jul 8. pii: S0168-8278(16)30321.
    PubMed     Text format     Abstract available


  169. YANG JD, Aqel BA, Pungpapong S, Gores GJ, et al
    Direct Acting Antiviral Therapy and Tumor Recurrence after Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma.
    J Hepatol. 2016 Jul 5. pii: S0168-8278(16)30318.
    PubMed     Text format    


  170. CHEUNG MC, Walker AJ, Hudson BE, Verma S, et al
    Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30314.
    PubMed     Text format     Abstract available


    June 2016
  171. CONTI F, Buonfiglioli F, Scuteri A, Crespi C, et al
    Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-related Cirrhosis Treated with Direct Acting Antivirals.
    J Hepatol. 2016 Jun 24. pii: S0168-8278(16)30303.
    PubMed     Text format     Abstract available


  172. FUNG J, Seto WK, Lai CL, Yuen J, et al
    Corrigendum to "Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy" [J Hepatol 2011;54:195-200].
    J Hepatol. 2016;64:1460.
    PubMed     Text format    


  173. COILLY A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry P, et al
    Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence after liver transplantation - The CO23 ANRS CUPILT study.
    J Hepatol. 2016 Jun 1. pii: S0168-8278(16)30253.
    PubMed     Text format     Abstract available


    May 2016
  174. WANG J, Shen T, Huang X, Renuka Kumar G, et al
    Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.
    J Hepatol. 2016 May 28. pii: S0168-8278(16)30241.
    PubMed     Text format     Abstract available


  175. MANDORFER M, Kozbial K, Schwabl P, Freissmuth C, et al
    Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.
    J Hepatol. 2016 May 27. pii: S0168-8278(16)30238.
    PubMed     Text format     Abstract available


  176. MANI SK, Zhang H, Diab A, Pascuzzi PE, et al
    EpCAM-Regulated Intramembrane Proteolysis Induces a Cancer Stem Cell-like Gene Signature in Hepatitis B Virus-infected Hepatocytes.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30208.
    PubMed     Text format     Abstract available


  177. HARTL J, Denzer U, Ehlken H, Zenouzi R, et al
    Validation of transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30209.
    PubMed     Text format     Abstract available


  178. SUN J, Ma H, Xie Q, Xie Y, et al
    Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30210.
    PubMed     Text format     Abstract available


  179. TSENG A, Wong DK
    Hepatotoxicity and Potential Drug Interaction with Ledipasvir/Sofosbuvir In HIV/HCV Infected Patients.
    J Hepatol. 2016 May 19. pii: S0168-8278(16)30201.
    PubMed     Text format     Abstract available


  180. LOK AS, Pan CQ, Han SB, Trinh HN, et al
    Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.
    J Hepatol. 2016 May 19. pii: S0168-8278(16)30202.
    PubMed     Text format     Abstract available


  181. VANDENBULCKE H, Moreno C, Colle I, Knebel JF, et al
    Alcohol intake increases the risk of hepatocellular carcinoma in patients with hepatitis C virus-related compensated cirrhosis: a prospective study.
    J Hepatol. 2016 May 12. pii: S0168-8278(16)30184.
    PubMed     Text format     Abstract available


  182. DEBING Y, Ramiere C, Dallmeier K, Piorkowski G, et al
    Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity.
    J Hepatol. 2016 May 9. pii: S0168-8278(16)30187.
    PubMed     Text format     Abstract available


  183. BULTEEL N, Sarathy PP, Forrest E, Stanley AJ, et al
    Factors Associated with Spontaneous Clearance of Chronic Hepatitis c Virus Infection: a Retrospective Case Control Study.
    J Hepatol. 2016 May 4. pii: S0168-8278(16)30182.
    PubMed     Text format     Abstract available


  184. MOENNE-LOCCOZ R, Severac F, Baumert TF, Habersetzer F, et al
    Usefulness of corticosteroids as first-line therapy in patients with acute severe autoimmune hepatitis.
    J Hepatol. 2016 May 4. pii: S0168-8278(16)30183.
    PubMed     Text format    


  185. COLOMBO M
    EASL Recognition Award Recipient 2016: Prof. Antonio Craxi.
    J Hepatol. 2016;64:1001-2.
    PubMed     Text format    


  186. PADEGIMAS A, Forde KA, Goldberg LR, Birati EY, et al
    Myo-pericarditis secondary to ledipasvir-sofosbuvir therapy.
    J Hepatol. 2016;64:1196-8.
    PubMed     Text format    


    April 2016
  187. BLANK A, Markert C, Hohmann N, Carls A, et al
    Myrcludex B: a first-in-human clinical study with a first-in-class hepatitis B and hepatitis D virus entry inhibitor.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30145.
    PubMed     Text format     Abstract available


  188. BOGOMOLOV P, Alexandrov A, Voronkova N, Macievich M, et al
    Interim results of a Phase Ib/IIa study of the entry inhibitor myrcludex B in chronic hepatitis D infected patients.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30148.
    PubMed     Text format     Abstract available


  189. FOSTER G
    Reply to: "High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme".
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30142.
    PubMed     Text format    


  190. GRAY E, O'Leary A, Stewart S, Bergin C, et al
    High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30143.
    PubMed     Text format    


  191. SARKAR S, Esserman DA, Skanderson M, Levin FL, et al
    Disparities in Hepatitis C Testing in U.S. Veterans Born 1945-1965.
    J Hepatol. 2016 Apr 26. pii: S0168-8278(16)30144.
    PubMed     Text format     Abstract available


  192. MAASOUMY B, Vermehren J, Welker MW, Bremer B, et al
    Clinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimens.
    J Hepatol. 2016 Apr 13. pii: S0168-8278(16)30108.
    PubMed     Text format     Abstract available


  193. REIG M, Marino Z, Perello C, Inarrairaegui M, et al
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution.
    J Hepatol. 2016 Apr 12. pii: S0168-8278(16)30113.
    PubMed     Text format     Abstract available


  194. BHAMIDIMARRI KR, Martin P
    Finally safe and effective treatment options for hepatitis C in hemodialysis patients.
    J Hepatol. 2016 Apr 9. pii: S0168-8278(16)30105.
    PubMed     Text format    


  195. LUNEMANN S, Martrus G, Holzemer A, Chapel A, et al
    Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C03:04 and modulate NK cell function.
    J Hepatol. 2016 Apr 4. pii: S0168-8278(16)30097.
    PubMed     Text format     Abstract available


  196. MEHTA SH, Thomas DL
    Doing the math on hepatitis C virus treatment.
    J Hepatol. 2016 Apr 2. pii: S0168-8278(16)30096.
    PubMed     Text format    


  197. BLONDOT ML, Bruss V, Kann M
    Intracellular transport and egress of hepatitis B virus.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  198. LUCIFORA J, Protzer U
    Attacking hepatitis B virus cccDNA - The holy grail to hepatitis B cure.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  199. TONG S, Revill P
    Overview of hepatitis B viral replication and genetic variability.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  200. LI W, Urban S
    Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  201. ALLWEISS L, Dandri M
    Experimental in vitro and in vivo models for the study of human hepatitis B virus infection.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  202. DURANTEL D, Zoulim F
    New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  203. SUREAU C, Negro F
    The hepatitis delta virus: Replication and pathogenesis.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  204. DUBUQUOY L
    Lipocalin 2 highlights the complex role of neutrophils in alcoholic liver disease.
    J Hepatol. 2016;64:770-2.
    PubMed     Text format    


  205. LEVRERO M, Zucman-Rossi J
    Mechanisms of HBV-induced hepatocellular carcinoma.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  206. BERTOLETTI A, Ferrari C
    Adaptive immunity in HBV infection.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  207. MAINI MK, Gehring AJ
    The role of innate immunity in the immunopathology and treatment of HBV infection.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  208. SEEGER C, Mason WS
    HBV replication, pathobiology and therapy: Unanswered questions.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  209. ROBERT O, Boujedidi H, Bigorgne A, Ferrere G, et al
    Decreased expression of the glucocorticoid receptor-GILZ pathway in Kupffer cells promotes liver inflammation in obese mice.
    J Hepatol. 2016;64:916-24.
    PubMed     Text format     Abstract available


    March 2016
  210. BRUNO S, Di Marco V, Iavarone M, Roffi L, et al
    Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
    J Hepatol. 2016 Mar 23. pii: S0168-8278(16)00075.
    PubMed     Text format     Abstract available


  211. DEBING Y, Moradpour D, Neyts J, Gouttenoire J, et al
    Update on Hepatitis E Virology:Implications for Clinical Practice.
    J Hepatol. 2016 Mar 7. pii: S0168-8278(16)30011.
    PubMed     Text format     Abstract available


  212. YOUNOSSI ZM, Stepanova M, Feld J, Zeuzem S, et al
    Sofosbuvir/Velpatasvir Improves Patient-Reported Outcomes in HCV Patients: Results from ASTRAL-1 Placebo-Controlled Trial.
    J Hepatol. 2016 Mar 5. pii: S0168-8278(16)30008.
    PubMed     Text format     Abstract available


  213. DESNOYER A, Pospai D, Le MP, Gervais A, et al
    Sofosbuvir-containing regimen for HCV infection in hemodialysis patients: 400 mg daily or only on the day of hemodialysis.
    J Hepatol. 2016 Mar 4. pii: S0168-8278(16)30010.
    PubMed     Text format     Abstract available


  214. YAMAMOTO N, Sato Y, Munakata T, Kakuni M, et al
    Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection.
    J Hepatol. 2016;64:547-55.
    PubMed     Text format     Abstract available


    February 2016
  215. VO M, Holz LE, Wong YC, English K, et al
    The extent and duration of acute hepatitis in mice is dominated by the function rather than by the survival of effector CD8 T cells.
    J Hepatol. 2016 Feb 25. pii: S0168-8278(16)00160.
    PubMed     Text format     Abstract available


  216. JACKA B, Applegate T, Poon AF, Raghwani J, et al
    Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.
    J Hepatol. 2016 Feb 25. pii: S0168-8278(16)00165.
    PubMed     Text format     Abstract available


  217. ZAHND C, Salazar-Vizcaya L, Dufour JF, Mullhaupt B, et al
    Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men.
    J Hepatol. 2016 Feb 24. pii: S0168-8278(16)00164.
    PubMed     Text format     Abstract available


  218. MOSTAFA A, Shimakawa Y, Medhat A, Mikhail NN, et al
    Excess mortality rate associated with hepatitis C virus infection: a community-based cohort study in rural Egypt.
    J Hepatol. 2016 Feb 24. pii: S0168-8278(16)00167.
    PubMed     Text format     Abstract available


  219. OZASLAN E, Efe C
    Further considerations in autoimmune hepatitis.
    J Hepatol. 2016 Feb 22. pii: S0168-8278(16)00154.
    PubMed     Text format    


  220. LOHSE AW, Chazouilleres O, Dalekos G, Drenth J, et al
    Clinical Practise Guidelines Autoimmune Hepatitis: Further considerations.
    J Hepatol. 2016 Feb 22. pii: S0168-8278(16)00159.
    PubMed     Text format    


  221. DAHARI H, Canini L, Graw F, Uprichard SL, et al
    HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.
    J Hepatol. 2016 Feb 20. pii: S0168-8278(16)00153.
    PubMed     Text format     Abstract available


  222. GOUTTENOIRE J, Moradpour D
    A Mouse Model for Hepatitis E Virus Infection.
    J Hepatol. 2016 Feb 15. pii: S0168-8278(16)00122.
    PubMed     Text format    


  223. STEVEN FOX D, McCombs JS
    Optimizing HCV Treatment - Moving Beyond the Cost Conundrum.
    J Hepatol. 2016 Feb 11. pii: S0168-8278(16)00089.
    PubMed     Text format    


  224. GENG Y, Zhao C, Wang Y
    Reply to "Rhesus macaques persistently infected with hepatitis E shed virus into urine".
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00085.
    PubMed     Text format    


  225. MARTIN NK, Vickerman P, Dore GJ, Grebely J, et al
    How should HCV treatment be prioritized in the direct-acting antiviral era? An economic evaluation including population prevention benefits.
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00086.
    PubMed     Text format     Abstract available


  226. HUANG F, Yang C, Zhou X, Yu W, et al
    Rhesus macaques persistently infected with hepatitis E shed virus into urine.
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00082.
    PubMed     Text format    


  227. ESLAM M, Hashem AM, Romero-Gomez M, Berg T, et al
    FibroGENE: A gene-based model for staging liver fibrosis.
    J Hepatol. 2016;64:390-8.
    PubMed     Text format     Abstract available


  228. PAVLIDES M, Banerjee R, Sellwood J, Kelly CJ, et al
    Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease.
    J Hepatol. 2016;64:308-15.
    PubMed     Text format     Abstract available


    January 2016
  229. FOSTER GR, Irving WL, Cheung MC, Walker AJ, et al
    Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jan 29. pii: S0168-8278(16)00065.
    PubMed     Text format     Abstract available


  230. WEBB G, Chen YY, Li KK, Neil D, et al
    Single-gene association between GATA-2 and autoimmune hepatitis: a novel genetic insight highlighting immunologic pathways to disease.
    J Hepatol. 2016 Jan 23. pii: S0168-8278(16)00051.
    PubMed     Text format     Abstract available


  231. UDOMPAP P, Mannalithara A, Heo N, Kim D, et al
    Increasing Prevalence of Cirrhosis among US Adults Aware or Unaware of their Chronic Hepatitis C Virus Infection.
    J Hepatol. 2016 Jan 22. pii: S0168-8278(16)00014.
    PubMed     Text format     Abstract available


  232. ALLWEISS L, Gass S, Giersch K, Groth A, et al
    Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation.
    J Hepatol. 2016 Jan 21. pii: S0168-8278(16)00017.
    PubMed     Text format     Abstract available


  233. YANG YH, Chen WC, Tsai YH, Chen PC, et al
    Reply to "Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection".
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00011.
    PubMed     Text format    


  234. HOOFNAGLE JH
    Hepatic Decompensation during Direct-Acting Antiviral Therapy of Chronic Hepatitis C.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00010.
    PubMed     Text format    


  235. YU ML
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00012.
    PubMed     Text format    


  236. MIDGARD H, Bjoro B, Maeland A, Konopski Z, et al
    Hepatitis C Reinfection Following Sustained Virological Response - Seven-Year Follow-Up Of Patients Infected Through Injecting Drug Use.
    J Hepatol. 2016 Jan 9. pii: S0168-8278(16)00003.
    PubMed     Text format     Abstract available


  237. BAUMERT TF, Schuster C, Cosset FL, Dubuisson J, et al
    Addressing the Next Challenges: a Summary of the 22nd International Symposium on Hepatitis C Virus and Related Viruses.
    J Hepatol. 2016 Jan 9. pii: S0168-8278(16)00004.
    PubMed     Text format     Abstract available


  238. YOUNOSSI ZM, Stepanova M, Estep M, Negro F, et al
    Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
    J Hepatol. 2016;64:29-36.
    PubMed     Text format     Abstract available


    December 2015
  239. CHAN HL, Ahn SH, Chang TT, Peng CY, et al
    Peginterferon Lambda for the Treatment of HBeAg-Positive Chronic Hepatitis B: A Randomized Phase 2b Study (LIRA-B).
    J Hepatol. 2015 Dec 28. pii: S0168-8278(15)00859.
    PubMed     Text format     Abstract available


  240. HULLEGIE SJ, Claassen MA, van den Berk GE, van der Meer JT, et al
    A 12-Week Treatment with Boceprevir, Peginterferon and Ribavirin for Acute Hepatitis C in HIV infected patients.
    J Hepatol. 2015 Dec 12. pii: S0168-8278(15)00805.
    PubMed     Text format     Abstract available


  241. MARCHAN-LOPEZ A, Dominguez-Dominguez L, Kessler-Saiz P, Jarrin-Estupinan ME, et al
    Liver Failure in Human Immunodeficiency Virus - Hepatitis C Virus Coinfection Treated with Sofosbuvir, Ledipasvir and Antiretroviral Therapy.
    J Hepatol. 2015 Dec 9. pii: S0168-8278(15)00799.
    PubMed     Text format    


  242. DYSON JK, McPherson S
    Reply to "Liver Failure in Human Immunodeficiency Virus - Hepatitis C Virus Coinfection Treated with Sofosbuvir, Ledipasvir and Antiretroviral Therapy".
    J Hepatol. 2015 Dec 9. pii: S0168-8278(15)00800.
    PubMed     Text format    


  243. PAPATHEODORIDIS G, Dalekos G, Sypsa V, Yurdaydin C, et al
    Page-B: Risk Score for Hepatocellular Carcinoma in Caucasians with Chronic Hepatitis B Under 5-Year Entecavir or Tenofovir Therapy.
    J Hepatol. 2015 Dec 8. pii: S0168-8278(15)00795.
    PubMed     Text format     Abstract available


    November 2015
  244. WELKER MW, Luhne S, Lange CM, Vermehren J, et al
    Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00792.
    PubMed     Text format     Abstract available


  245. BILLIOUD G, Kruse RL, Carrillo M, Whitten-Bauer C, et al
    In vivo Reduction of Hepatitis B Virus Antigenemia and Viremia by Antisense Oligonucleotides.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00790.
    PubMed     Text format     Abstract available


  246. RAY KIM W, Berg T, Asselah T, Flisiak R, et al
    Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00770.
    PubMed     Text format     Abstract available


  247. HELSEN N, Debing Y, Paeshuyse J, Dallmeier K, et al
    Stem cell-derived hepatocytes: a novel model for hepatitis E virus replication.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00771.
    PubMed     Text format     Abstract available


  248. LEMPP FA, Mutz P, Lipps C, Wirth D, et al
    Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor.
    J Hepatol. 2015 Nov 11. pii: S0168-8278(15)00736.
    PubMed     Text format     Abstract available


    September 2015
  249. YAN M, Ha J, Aguilar M, Bhuket T, et al
    Birth Cohort-Specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis, Treatment, and Long-term Survival.
    J Hepatol. 2015 Sep 16. pii: S0168-8278(15)00623.
    PubMed     Text format     Abstract available


  250. KHATRI A, Menon R
    Reply to comments on: Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Sep 5. pii: S0168-8278(15)00612.
    PubMed     Text format    


  251. CHTIOUI H, Buclin T
    Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Sep 4. pii: S0168-8278(15)00610.
    PubMed     Text format    


    August 2015
  252. GRANCINI V, Trombetta M, Lunati ME, Zimbalatti D, et al
    Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00553.
    PubMed     Text format     Abstract available


  253. HUNG GY, Horng JL, Yen HJ, Lee CY, et al
    Changing Incidence Patterns of Hepatocellular Carcinoma Among Age Groups in Taiwan.
    J Hepatol. 2015 Aug 6. pii: S0168-8278(15)00534.
    PubMed     Text format     Abstract available


    June 2015
  254. LAMPERTICO P, Invernizzi F, Vigano M, Loglio A, et al
    The long-term benefits of nucleos(t)ide analogs on esophageal varices in compensated HBV cirrhotics with no or small esophageal varices: A 12-year prospective cohort study.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00397.
    PubMed     Text format     Abstract available


  255. ALMISHRI W, Deans J, Swain MG
    Rapid activation and hepatic recruitment of innate-like regulatory B cells after invariant NKT cell stimulation in mice.
    J Hepatol. 2015 Jun 18. pii: S0168-8278(15)00398.
    PubMed     Text format     Abstract available


  256. KHATRI A, Menon R, Marbury TC, Lawitz E, et al
    Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Jun 10. pii: S0168-8278(15)00387.
    PubMed     Text format     Abstract available


    April 2015
  257. PAWLIK TM, Soubrane O
    Metabolic syndrome-associated hepatocellular carcinoma: questions still unanswered.
    J Hepatol. 2015 Apr 7. pii: S0168-8278(15)00245.
    PubMed     Text format    


  258. PEIFFER KH, Akhras S, Himmelsbach K, Hassemer M, et al
    Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level.
    J Hepatol. 2015;62:791-8.
    PubMed     Text format     Abstract available


  259. MATHURIN P, Bataller R
    Trends in the management and burden of alcoholic liver disease.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


  260. ARROYO V, Moreau R, Jalan R, Gines P, et al
    Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


    January 2015
  261. NEGRO F
    Are statins a remedy for all seasons?
    J Hepatol. 2015;62:8-10.
    PubMed     Text format    


    December 2014
  262. SOHN W, Paik YH, Cho JY, Lim HY, et al
    Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
    J Hepatol. 2014 Dec 13. pii: S0168-8278(14)00927.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: